Janus Henderson Group PLC Has $35.59 Million Stake in Contineum Therapeutics, Inc. $CTNM

Janus Henderson Group PLC increased its position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) by 11.7% in the 1st quarter, Holdings Channel reports. The firm owned 2,734,836 shares of the company’s stock after buying an additional 285,857 shares during the quarter. Janus Henderson Group PLC owned about 0.07% of Contineum Therapeutics worth $35,594,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. acquired a new stake in Contineum Therapeutics during the fourth quarter worth $43,000. Strs Ohio acquired a new position in shares of Contineum Therapeutics in the 1st quarter valued at $27,000. Royal Bank of Canada lifted its holdings in shares of Contineum Therapeutics by 73.5% during the 1st quarter. Royal Bank of Canada now owns 5,794 shares of the company’s stock worth $76,000 after acquiring an additional 2,454 shares during the period. Bank of America Corp DE lifted its holdings in shares of Contineum Therapeutics by 500.0% during the 3rd quarter. Bank of America Corp DE now owns 7,236 shares of the company’s stock worth $85,000 after acquiring an additional 6,030 shares during the period. Finally, Qube Research & Technologies Ltd acquired a new stake in shares of Contineum Therapeutics during the 2nd quarter valued at about $43,000.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on CTNM. Royal Bank Of Canada upped their target price on shares of Contineum Therapeutics from $22.00 to $23.00 and gave the company an “outperform” rating in a research note on Friday. Wall Street Zen upgraded shares of Contineum Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Morgan Stanley lifted their price objective on Contineum Therapeutics from $14.00 to $16.00 and gave the company an “equal weight” rating in a report on Thursday, May 14th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Contineum Therapeutics in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $20.25.

Contineum Therapeutics Stock Performance

Shares of NASDAQ CTNM opened at $15.49 on Monday. Contineum Therapeutics, Inc. has a 52-week low of $5.07 and a 52-week high of $16.91. The business has a fifty day moving average of $13.64 and a two-hundred day moving average of $13.66. The stock has a market cap of $579.17 million, a PE ratio of -8.95 and a beta of 0.74.

Contineum Therapeutics (NASDAQ:CTNM) last posted its earnings results on Thursday, July 30th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.05. Analysts predict that Contineum Therapeutics, Inc. will post -1.68 earnings per share for the current year.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.